Miami Jewish Health Systems

Miami, Florida 33137

1 studies enrolling now · 32 studies all time

What they study most

Agitation and Aggression in Alzheimer's Disease, Alzheimer Disease, Alzheimer's Disease, Alzheimer´s Disease, Dementia, Dementia of Alzheimer's Type, Dementia of the Alzheimer's Type, Early Alzheimer's Disease, Irregular Sleep Wake Rhythm Disorder, Mild Cognitive Impairment, Mild to Moderate Alzheimer Disease

Studies at this site

• [18F]PI-2620 Phase 3 Histopathological Study — Recruiting now
• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease — Running, not enrolling
• A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) — Completed
• A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD) — Running, not enrolling
• Memory Improvement Through Nicotine Dosing (MIND) Study — Completed
• Escitalopram for Agitation in Alzheimer's Disease — Running, not enrolling
• A Study of Semorinemab in Patients With Moderate Alzheimer's Disease — Completed
• Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION) — Completed
• A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease — Stopped early
• 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
• AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext — Completed
• A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease — Completed
• A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder — Completed
• 18F-AV-1451 Autopsy Study — Completed
• Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease — Stopped early
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early
• A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease — Completed
• Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants — Completed
• An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease — Stopped early
• A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease — Stopped early
• Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease — Completed
• A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease — Completed
• A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type — Completed
• Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease — Completed
• Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment — Stopped early
• Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07 — Completed
• A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy — Completed
• Effect of NeuroAD on the Cognitive Function of Alzheimer Patients — Completed
• Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease — Completed
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed